Grants for Independent school districts - Federal

The National Cancer Institute (NCI) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for the RNA Modifications Driving Oncogenesis (RNAMoDO) Initiative. It aims to promote mechanistic research in the emerging area of RNA modifications that drive oncogenesis, with a focus on the central role of RNA modifications in translational reprogramming of cancer cells. RNA modifications have been recognized to exert a substantial impact on gene expression and function and their de-regulation has been linked to the cancer phenotype. In particular, recent insights point to a crucial role for mRNA, tRNA, and rRNA modifications in translational reprogramming during tumor initiation, progression, and adaptation to therapy. However, the molecular mechanisms underlying this reshaping of the translatome caused by dynamic changes in RNA modifications, and especially the interplay between different RNA modifications within and across RNA molecules during translation, are not understood and represent the focus of this initiative. Historically, the research community has largely pursued investigations of RNA modifications by studying single RNA species and modification types. However, elucidating how dysregulation of mRNA, tRNA, and rRNA modifications reprograms translation to drive oncogenesis is not likely feasible for any single research laboratory, but will require the combination of expertise in mRNA, tRNA and rRNA biology, translational regulation, and cancer research. To stimulate progress in this emerging field, the RNAMoDO program will support collaborative research projects, preferably using an MPI structure, on how modifications in mRNA, tRNA, and rRNA molecules can drive the oncogenic process through translational reprogramming. To be responsive to the NOFO, each project will also explore the impact of interactions between modifications residing on the same or different RNA molecules during translation. This Notice of Intent to Publish (NOITP) is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in the early Fall of 2024, with an expected application due date in November 2024. The NOFO will utilize the U01 mechanism for Research Project Cooperative Agreement (Clinical Trial Not Allowed). Potential applicants are encouraged to view the presentation of this initiative to the NCI Board of Scientific Advisors (BSA), available at: (https://videocast.nih.gov/watch=54423) beginning at 1 hour, 32 minutes, 52 seconds. Presentation slides are downloadable at https://deainfo.nci.nih.gov/advisory/bsa/0324/Maas.pdf.

This funding opportunity is designed to support partnerships that help low-income students successfully transition from middle school to college through mentoring, academic support, and financial aid education.

This funding opportunity supports researchers from various fields in developing innovative methods to study brain changes over time, focusing on both healthy individuals and those with specific cognitive or emotional challenges.

This funding opportunity supports researchers exploring heart, lung, and blood diseases and sleep disorders by providing access to valuable biospecimen collections for preliminary data generation.

This grant provides financial support for senior graduate students from diverse backgrounds to complete their dissertations in aging research, promoting a more inclusive scientific workforce.

The U.S. Fish and Wildlife Service (FWS) is the premier government agency dedicated to the conservation, protection, and enhancement of fish, wildlife and plants, and their habitats. We are the only agency in the federal government whose primary responsibility is the conservation and management of these important natural resources for the American public.FWS origins date back to 1871 when Congress established the U.S. Fish Commission to study the decrease in the nations food fishes and recommend ways to reverse that decline. Today, we are a diverse and largely decentralized organization, employing about 8,000 dedicated professionals working out of facilities across the country, including a headquarters office in Falls Church, Virginia, and eight Regional offices.The National Infrastructure Partnerships initiative of the US Fish and Wildlife Service (FWS) encourages National Wildlife Refuge System field stations to partner with local, regional, and national nonprofit organizations, other land management groups, state and tribal partners, and others to accomplish projects that:i. promote the stewardship of Refuge System resources through habitat maintenance, restoration, and improvement, andii. support the operation and maintenance of the Refuge System through constructing, operating, maintaining, or improving the facilities and services of the Refuge System.The goals of the initiative are to enable local communities to play a more active role in increasing outdoor recreation opportunities on refuge lands and waters, to be more focused and deliberate in using partnerships to help FWS address infrastructure repair and improvement needs such as proactive maintenance and the maintenance backlog, and to enhance wildlife habitat.Additionally, this initiative can help address multiple FWS priorities as a catalyst for:Economic and Conservation EnhancementCareer Training and Mentoring Opportunities for Youth and AdultsEquity and Inclusion in Conservation and RecreationClimate and Wildlife ResilienceCommunity HealthSuccessful projects will address identified FWS priorities or projects at FWS sites that enhance the visitor experience, promote wildlife-dependent outdoor recreation, provide sustainable wildlife habitat, provide career training and mentoring opportunities, and engage the community in opportunities to participate in wildlife-dependent outdoor recreation on FWS lands and waters.See Full Announcement for additional eligibility requirements.

This funding opportunity supports physician-scientists with clinical doctorate degrees who are transitioning to independent research careers in non-malignant hematology, enabling them to advance their research on blood disorders.

This funding opportunity supports research projects that develop and test strategies to overcome barriers to HIV prevention for individuals who use substances, particularly focusing on marginalized groups such as women, transgender individuals, and those involved in the criminal justice system.

This grant provides funding for innovative technology development projects that aim to create new tools and methods for advancing biomedical research, focusing on prototypes that address significant technical challenges.

This funding opportunity supports U.S. higher education institutions and nonprofits in training predoctoral and postdoctoral researchers to advance interdisciplinary research on Alzheimer's Disease and related dementias.

This funding opportunity provides financial support to local governments and school districts for ecological restoration projects and educational initiatives aimed at enhancing native landscapes and wildlife habitats in the Willamette Valley.

This funding opportunity supports early-career researchers from diverse backgrounds in advancing their studies on Alzheimer's Disease-Related Dementias, helping them transition from mentored postdoctoral positions to independent faculty roles.

This funding opportunity supports conservation projects for at-risk species in the U.S. by providing financial assistance to a diverse range of applicants, including nonprofits, educational institutions, and government entities, to implement proactive measures that prevent species from needing federal protection.

This grant provides funding to organizations that support programs helping older adults and individuals with disabilities manage chronic diseases while improving their behavioral health through education and community partnerships.

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs

This funding opportunity supports a wide range of research projects aimed at improving the understanding, prevention, diagnosis, and treatment of Alzheimer's Disease and related dementias, particularly focusing on underserved populations and health disparities.

This funding opportunity supports research partnerships between technology developers and academic researchers to optimize and evaluate digital mental health interventions, particularly for underserved populations.

This funding opportunity supports research projects aimed at developing safe and effective medications for treating substance use disorders, particularly for substances like cocaine, methamphetamine, and cannabis, and is open to a wide range of eligible institutions and organizations.